Cns Pharmaceuticals, Inc. · NASDAQ:CNSP
Cns Pharmaceuticals — Investor Presentation (September 2025)
20 slides from Cns Pharmaceuticals's investor presentation, September 2025
Slide 1: NASDAQ: CNSP September 2025
NASDAQ: CNSP September 2025 1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation incorporates information from materials filed with the SEC and contains forward-looking statements. All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial pos
Slide 3: Overview
Overview Developing Anti-Cancer Drug Candidates for the Treatment of Primary and Metastatic Brain Cancers Strong Financial Position – over $12M at Q2 close Proven Clinical Development "Engine" with Global Trial Site Network in Place to Accelerate Complex CNS Focused Trials Advancing Lead Product Can
Slide 4: A Focused and Targeted CNS Oncology Pipeline
A Focused and Targeted CNS Oncology Pipeline Program Indication Preclinical Phase 1 Phase 2 Phase 3 Highlights • Studied in over 350 patients to date Glioblastoma TPI 287 Multiforme (GBM) • Plan to engage with regulators to design potential registration study in 2025 A Much Bigger Story Beyond GBM P
Slide 5: Established "Engine" to Execute Global CNS Clinical Trials
Established "Engine" to Execute Global CNS Clinical Trials Key Learnings and Established Network From Berubicin Monotherapy Potentially Pivotal Trial 5 27 46 Countries 247 Months to Fully Enroll the Trial Patients Enrolled in an CNS Focused Orphan GBM Indication Clinical Trial Sites Successfully Bui
Slide 6: Proven Clinical Development Infrastructure Optimized for Brain Cancer Drug Development
Proven Clinical Development Infrastructure Optimized for Brain Cancer Drug Development Relationships • Deliberate establishment of a global, CNS focused network • Commitment to work in this disease • Deep understanding of the landscape of clinical trials in GBM Program Development Infrastructure & E
Slide 7: Glioblastoma Multiforme (GBM)
Glioblastoma Multiforme (GBM) 12 – 18 MONTHS One of the most aggressive, Average Life Expectancy1 deadly and treatment-resistant cancers that forms in the brain >50,000 New Cases in the 8 Major Current standard of care Markets2 Each Year3 ineffective in ~60% of patients >151,000 Can affect cognition
Slide 8: The Blood Brain Barrier (BBB)
The Blood Brain Barrier (BBB) Highly Selective, Semi-Permeable Barrier that Separates the Circulating Blood from the Brain Key Functions • Protection: • Blocks toxins, pathogens and potentially harmful molecules from entering the brain by transporters that bind to these substances and deliver them b
Slide 9: TPI 287
TPI 287 Late Stage, Novel Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies 9
Slide 10: TPI 287: A Novel Taxane Derivative
TPI 287: A Novel Taxane Derivative • Taxanes • A class of chemotherapy that binds to microtubules and prevents them from functioning normally, which stops cancer cells from dividing TPI 287 • A substrate for P-glycoprotein (Pgp), which is upregulated in cells that become taxane-resistant, and is par
Slide 11: Readily Penetrates the Blood Brain Barrier in Animal Models
Readily Penetrates the Blood Brain Barrier in Animal Models 11
Slide 12: Clinical Trials with TPI 287
Clinical Trials with TPI 287 ✓ Evaluated in multiple Phase 1 Engaging with regulators to ✓ and Phase 2 studies advance into registrational study Fast Track Orphan Drug Designation ✓ ✓ Designation with 7 years market exclusivity in the U.S. 12
Slide 13: TPI 287 in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
TPI 287 in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma Progression-Free Survival Overall Survival Median PFS: 5.5 mo [95% C.I. 4.1, 8.2] 6-month PFS: 40% Median OS: 13.4 mo [95% C.I. 10.9, 17.9] 12-month OS: 64% 13
Slide 14: Improved GBM Survival in Combination with Bevacizumab
Improved GBM Survival in Combination with Bevacizumab * Graphs represent aggregate data from multiple studies 14
Slide 15: Berubicin
Berubicin Evaluation of Strategic Options May Provide Potential for Upside 15
Slide 16: Summary of Primary Analysis
Summary of Primary Analysis Berubicin Showed clinically relevant outcomes comparable to Lomustine across multiple endpoints1 Safety profile continues to be favorable, including the absence of anthracycline related cardiotoxicity Reported Primary Analysis of Analysis of outcomes are ongoing, includin
Slide 17: Berubicin Demonstrated Comparable Overall Survival Compared to Standard of Care, Lomustine
Berubicin Demonstrated Comparable Overall Survival Compared to Standard of Care, Lomustine 17
Slide 18: Financial Snapshot
Financial Snapshot NASDAQ: CNSP Cash Expected to Fund Operations Into the Second Half of 2026 $12.1 Million ~42k ~$3.6 Million Cash* Volume Market Cap As of June 30, 2025 Average 3 months As of September 2, 2025 ~$4.5 Million *Cash Position Includes Net Proceeds of $4.5 Million Raised in May 2025 18
Slide 19: Management Team
Management Team John M. Climaco, Esq PRESIDENT & CHIEF EXECUTIVE OFFICER Twenty-one years experience managing the operations, strategies and finances of public and private lifescience companies. Christopher S. Downs, CPA CHIEF FINANCIAL OFFICER Nearly 20 years of finance and investment banking exper
Slide 20: NASDAQ: CNSP
Investor & Media Relations: JTC Team, LLC NASDAQ: CNSP Jenene Thomas 908.824.0775 [email protected] 20
CNS Pharmaceuticals — Investor Presentation (September 2025) on 6ix